The pathogenetic role of undifferentiated connective tissue dysplasia in congenital nephropathies in children
DOI:
https://doi.org/10.52673/18570461.26.1-80.09Keywords:
biomarkers, children, dysplasia, connective tissueAbstract
Congenital anomalies of the connective tissue represent one of the most common congenital malformations of the urinary system encountered in the pediatric population. At the same time, one of the main pathogenetic factors of renal function impairment in congenital nephropathies is hypoxia, at the same time, hypoxia is considered one of the basic factors affecting connective tissue metabolism, thereby creating a vicious circle. Therefore, in order to facilitate diagnosis, staging, long-term follow-up and prevention of complications, in-depth studies are required on the evaluation of certain biomarkers related to the pathophysiology of connective tissue. The article represents a complex retrospective and prospective analysis of a group consisting of 100 patients who underwent surgical treatment for reno-urinary malformations during the period 2013–2025. The prospective analysis of medical records was performed in 35 patients with congenital hydronephrosis, in 45 – with vesicoureteral reflux and in 20 – with megaureterohydronephrosis. The evaluation of PCE(BChE) levels, as well as other biomarkers such as total protein, and the functionality of serum N-acetyl-beta-D-glucosaminidase (NAG), can provide valuable information about the prognosis of patients in various clinical situations and could improve prognostic accuracy and the establishment of new effective pathogenetic treatment approaches in children with vesicoureteral reflux (VUR) and congenital developmental anomalies associated with connective tissue dysplasia. Further in-depth studies are necessary, aimed at reducing the incidence of connective tissue dysplasia in congenital nephropathies in children.
References
1. Kryganova, T.A.; Aksenova, M.Ye.; Dlin, V.V. Puzyrno-mochetochnikovyy reflyuks i yego oslozhneniya u detey v zavisimosti ot stepeni vyrazhennosti displazii soyedinitel’noy tkani, in: Ros Vestn Perinatol Pediat. 2016; 4:93-97. https://doi.org/10.21508/1027-4065-2016-61-4-93-97
2. Povshedna, T.Yu.; Shevchuk, D.V.; Korniychuk, N.M. The role of timely treatment of congenital malformations of the urinary system in the prevention of chronic renal failure in children, in: Biol Res, 2015, 1:423-429.
3. Semyanchuk, V.B. Prevalence of manifestations of undifferentiated connective tissue dysplasia in children of Prykarpattia, patients with bronchial asthma, in: Act Prob Mod Med, 2015, 15(2):149-154.
4. Lukina, T.S. Evaluation of the oxyproline marker and its value in women with undiferentiated connective tissue dysplasia, in: Mod Med, 2015, Top Issues 6-7(41):6-10.
5. Maydannyk, V.H.; Burlaka, Ye.A. State of metabolic hypoxic disorders in diabetic nephropathy in children, in: Exp Clin Physiol Biochem, 2015; 4:47-55. https://doi.org/10.25040/ecpb2015.04.047
6. Sakashita, M.; Tanaka, T.; Inagi, R. Metabolic Changes and Oxidative Stress in Diabetic Kidney Disease, in: Antioxidants (Basel). 2021, Jul 19;10(7):1143. https://doi.org/10.3390/antiox10071143
7. Jovičić, S.M. Enzyme ChE, cholinergic therapy and molecular docking: Significant considerations and future perspectives, in: International Journal of Immunopathology and Pharmacology. 2024;38. https://doi.org/10.1177/03946320241289013
8. Markuskova, L.; Javorova, Rihova Z.; Fazekas, T., et al. Serum butyrylcholinesterase as a marker of COVID-19 mortality: Results of the monocentric prospective observational study, in: Chem Biol Interact. 2023;381:110557. https://doi.org/10.1016/j.cbi.2023.110557
9. Kadurina, T.I.; Gnusayev, S.F.; Arsent’yev, V.G. Chast’ 2. Poliorgannyye narusheniya pri displazii soyedinitel’noy tkani u detey. Algoritmy diagnostiki. Taktika vedeniya. Proyekt rossiyskikh rekomendatsiy, in: Meditsinskiy vestnik Severnogo Kavkaza, 2016;2(2):239-263. https://doi.org/10.14300/mnnc.2016.11050
10. Dorota, Stefanicka-Wojtas; Donata, Kurpas. Personalised Medicine – Implementation to the Healthcare System in Europe (Focus Group Discussions), in: J Pers Med. 2023, Feb 21;13(3):380. https://doi.org/10.3390/jpm13030380
11. Kohl, S.; Avni, F.E.; Boor, P.; Capone, V., et al. Definition, diagnosis and clinical management of non-obstructive kidney dysplasia: a consensus statement by the ERKNet Working Group on Kidney Malformations, in: Nephrol Dial Transplant. 2022, Nov 23;37(12):2351-2362. https://doi.org/10.1093/ndt/gfac207
12. Shcherbo, S.N.; Shcherbo, D.S. Laboratornaya diagnostika kak osnova meditsiny 5P, in: Vestnik RGMU. 2019; (1): 5-14. https://doi.org/10.24075/vrgmu.2018.095
13. Mahmoud, A.H.; Talaat, I.M.; Tlili, A. and Hamoudi, R. Congenital anomalies of the kidney and urinary tract, in: Front. Med. 2024; 11:1384676. https://doi.org/10.3389/fmed.2024.1384676
14. Uitto, J.; Lichtenstein, J.R. Defects in the biochemistry of collagen in diseases of connective tissue, in: J Invest Dermatol. 1976, Feb;66(02):59-79. https://doi.org/10.1111/1523-1747.ep12481404
15. Simsek B.; Karacaer, O.; Karaca, I. Urine products of bone breakdown as markers of bone resorption and clinical usefulness of urinary hydroxyproline: an overview, in: Chinese Medical Journal 117(2):291-295, 2004.
16. Fischbach, F. Urine Hydroxyproline, in: A Manual of Laboratory and Diagnostic Tests. Lippincott Williams & Wilkins, USA, 8 ed. 2009, 278-279.
17. Chen, Y.; Dai, R.; Cheng, M., et al. Status and role of the ubiquitin-proteasome system in renal fibrosis, in: Biomed Pharmacother. 2024 Sep;178:117210. https://doi.org/10.1016/j.biopha.2024.117210
18. Xia, G.; Guo, Y.; Zhang, J.; Han, M.; Meng, X.; Lv J. An Overview of the Deubiquitinase USP53: A Promising Diagnostic Marker and Therapeutic Target, in: Curr Protein Pept Sci. 2024;25:708-18. https://doi.org/10.2174/0113892037292440240518194922
19. Shaid; S.; Brandts, C.H.; Serve, H.; Dikic, I. Ubiquitination and selective autophagy, in: Cell Death Differ. 2013;20:21-30. https://doi.org/10.1038/cdd.2012.72
20. Chiang, C.-K.; Hsu, S.-P.; Wu C.-T., et al. Endoplasmic Reticulum Stress Implicated in the Development of Renal Fibrosis, in: Mol. Med. 2011; 17: 1295-1305. https://doi.org/10.2119/molmed.2011.00131
21. Chen, X.; Yong, H.; Chen, M., et al. TRIM21 attenuates renal carcinoma lipogenesis and malignancy by regulating SREBF1 protein stability, in: J Exp Clin Cancer Res. 2023;42:34. https://doi.org/10.1186/s13046-022-02583-z
22. Labbadia, J., Morimoto, R.I. The biology of proteostasis in aging and disease, in: Annu Rev Biochem. 2015;84:435-64. https://doi.org/10.1146/annurev-biochem-060614-033955
23. Chen, J.H.: Wu, C.H.: Chiang, C.K. Therapeutic Approaches Targeting Proteostasis in Kidney Disease and Fibrosis, in: Int J Mol Sci. 2021 Aug 12;22(16):8674. https://doi.org/10.3390/ijms22168674
24. Navarro-Betancourt, J.R.; Cybulsky, A.V. The IRE1α pathway in glomerular diseases: The unfolded protein response and beyond, in: Front Mol Med. 2022 Sep 26;2:971247. https://doi.org/10.3389/fmmed.2022.971247
25. Nangaku, M. Mechanisms of Tubulointerstitial Injury in the Kidney: Final Common Pathways to End-stage Renal Failure, in: Intern. Med. 2004; 43:9-17. https://doi.org/10.2169/internalmedicine.43.9
26. Inoue, T.; Maekawa, H.; Inagi, R. Organelle crosstalk in the kidney, in: Kidney Int. 2019; 95:1318-1325. https://doi.org/10.1016/j.kint.2018.11.035
27. Kurts, C.; Panzer, U.; Anders, H.-J.; Rees, A.J. The immune system and kidney disease: Basic concepts and clinical implications, in: Nat. Rev. Immunol. 2013;13: 738-753. https://doi.org/10.1038/nri3523
28. Tampe, D.; Zeisberg, M. Potential approaches to reverse or repair renal fibrosis. in: Nat. Rev. Nephrol. 2014;10:226-237. https://doi.org/10.1038/nrneph.2014.14
